Treatment with oral anticoagulants with vitamin K antagonists (eg, warfarin) or non-vitamin K antagonist oral anticoagulants could effectively reduce the risk of ischemic stroke in patients with atrial fibrillation (AF). However, the risk of further intracranial hemorrhage (ICH) and the benefit of stroke risk reduction with the use of oral anticoagulants for AF patients with previous ICH remain unclear, given that such patients were excluded from randomized trials. In this nationwide population-based study, we investigated the risk of ischemic stroke and ICH among 12 917 AF patients with a history of ICH, who were allocated into 3 groups, that is, no treatment (63.6%), antiplatelet therapy (27.5%), and warfarin (8.9%). We found that the use of antiplatelet agents did not significantly reduce the risk of ischemic stroke, but it did increase the risk of ICH for patients with previous ICH; thus, antiplatelet therapy should not be used in AF patients with a history of ICH for stroke prevention. The use of warfarin was associated with a lower risk of ischemic stroke, but also a higher risk of ICH in comparison with AF patients who did not receive antithrombotic therapy. After considering the risk/benefit ratio, warfarin use may be beneficial for Asian AF patients with a CHA 2 DS 2 -VASc score ≧6. Whether the use of non-vitamin K antagonist oral anticoagulants could lower the threshold for treatment deserves further study. See p 1540.
Angiographic and Intracoronary Manifestations of Coronary Fibromuscular Dysplasia
Angiographic manifestations of coronary fibromuscular dysplasia (FMD) aside from dissection were considered rare. However, we observed several coronary angiographic abnormalities in patients with extracardiac FMD. In this 32-patient case series, we reported the angiographic appearance suggestive of coronary FMD in patients with extracardiac multifocal FMD. The most common coronary angiographic abnormality was arterial tortuosity (corkscrew appearance), which was present to at least a mild degree in all patients, and ≈90% had at least moderate or severe tortuosity. Irregular stenosis of varying lengths (≈60%) and diffuse/segmental arterial enlargement (≈56%) were also commonly observed. However, smooth stenosis was less commonly observed. These angiographic abnormalities were remote from dissected segments, which were present in ≈40% of this cohort. Fifteen patients had optical coherence tomography of the abnormal segments showing many abnormalities not typically observed with atherosclerosis, including multiple areas of patchy or diffuse intimal, medial, or adventitial abnormalities with thickening/accumulation of varied reflectivities, macrophage infiltration, loss/duplication of elastic membranes, and cavitation. Many of these angiographic and intracoronary features are novel and not previously described in patients with FMD. Recognizing these potential angiographic and intracoronary features of coronary FMD could help clinicians improve the diagnosis of coronary FMD and better understand the potential link to spontaneous coronary artery dissection and other symptomatic presentations in patients with FMD. Furthermore, future prospective studies evaluating such features may help risk stratify the predisposition to coronary dissection in patients with FMD. See p 1548.
Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials
Representation by age is important to support translation of clinical trial results to treatment of older patients in practice; however, historically, older patients have been underrepresented in clinical trial populations. Our examination of trends in the enrollment of patients with non-ST-segment-elevation acute coronary syndrome according to age in 11 phase III trials of antithrombotic therapy from 1994 to 2010 showed that, despite the relaxation of age criteria for inclusion in trials during more recent time periods, there were minimal changes in the age distribution of enrolled patients. The proportion of enrolled patients aged ≥75 years remained disproportionate to their representation in clinical practice. However, across all age groups, mortality fell by approximately half over the 17-year study period despite an increase in comorbidities and as a result of increased use of pharmacotherapies and increased use of invasive treatments. The need to pool trial data to obtain an adequate sample size within the older patient groups to demonstrate these favorable trends highlights potential concerns about extrapolating the results from a single trial to the aging population in clinical practice-such concerns that may lead to underuse of guideline-recommended care among older, inherently higher-risk patients who may derive greater ischemic benefit, but who may also be at greater risk for adverse effects. To ensure that the clinical trial results that form the basis of evidence-based care adequately reflect the benefits and risks of treatment in the aging population, every effort must be made to ensure that enrollment in clinical trials is representative by age. See p 1560.
Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease
Current guidelines recommend statins in the primary prevention of cardiovascular disease on the basis of predicted cardiovascular risk without directly considering the expected benefits of statin therapy based on the available randomized, controlled trial evidence. The Cholesterol Treatment Trialists (CTT) have demonstrated that the relative benefit of statin therapy is greater at lower levels of risk. Furthermore, because the reduction in cardiovascular risk per 1-mmol/L reduction Volume 133 ◼ Number 16 ◼ April 19, 2016
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April 19, 2016 in low-density lipoprotein cholesterol is close to constant, as reported by the CTT, then the potential benefit for each individual should depend on the individual's baseline low-density lipoprotein cholesterol and baseline risk. We now report a new model based on individualized predicted statin benefit to select individuals for statin therapy for the primary prevention of cardiovascular disease. This model integrates both the predicted risk and relative risk reductions observed in randomized trials. We show that an individualized statin benefit approach identifies 9.5 million lower-risk Americans individuals who have equal or greater expected benefit from statins in primary prevention than higher-risk individuals. Treatment of these younger individuals (who frequently have higher levels of low-density lipoprotein cholesterol) could potentially prevent an additional 266 000 atherosclerotic events over 10 years compared with standard approaches. An individualized benefit approach may therefore help identify patients who meaningfully benefit from statins in future guideline recommendations. The concept of individualized statin benefit could also be helpful to physicians and patients in discussing the potential merits and limitations of statin preventive therapy. See p 1574.
Transcatheter Tricuspid Valve-in-Valve Implantation for the Treatment of Dysfunctional Surgical Bioprosthetic Valves: An International, Multicenter Registry Study
Stenosis or regurgitation of bioprostheses is inevitable after heart valve replacement. Management of bioprosthetic valve dysfunction is complicated by the risks of redo sternotomy in patients who are often frail and ill. Transcatheter valve implantation has proved to be an effective alternative to repeat surgical valve replacement in patients with dysfunctional aortic, pulmonary, and mitral bioprostheses. In this multicenter registry study of >150 patients with dysfunction of surgical tricuspid valve prostheses, we found that transcatheter tricuspid valve-in-valve implantation is technically feasible with a few procedural complications across a wide range of valve sizes, patient ages, and underlying cardiovascular conditions, with good short-term hemodynamic and clinical outcomes. Over a median follow-up of 13.3 months, valve function generally remained good. These findings support tricuspid valve-in-valve implantation as a clinically useful and durable intervention in most patients, even in many of those with severe symptoms and comorbidities. See p 1582.
